In a report released yesterday, Jason Butler from JMP Securities reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $4.91.
Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Quoin Pharmaceuticals, and Gamida Cell. According to TipRanks, Butler has an average return of -1.8% and a 44.42% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quoin Pharmaceuticals with a $15.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $444.00 and a one-year low of $3.58. Currently, Quoin Pharmaceuticals has an average volume of 1.73M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Read More on QNRX:
- Wilsons Sticks to Their Buy Rating for CSL (CMXHF)
- Macquarie downgrades Vicinity Centres (CNRAF) to a Hold
- Analysts Offer Insights on Technology Companies: Unity Software (U) and Blend Labs (BLND)
- Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Pear Therapeutics (PEAR)
- Lucira Health (LHDX) Receives a Buy from LifeSci Capital